Pacer Advisors
KRYS icon

Pacer Advisors’s Krystal Biotech KRYS Stock Holding History

Pacer Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Sell
1,315
-1,232
-48% -$368K ﹤0.01% 1570
2026
Q1 		$658K Buy
2,547
+835
+49% +$222K ﹤0.01% 1384
2025
Q4 		$422K Buy
1,712
+1,105
+182% +$233K ﹤0.01% 1828
2025
Q3 		$107K Buy
607
+152
+33% +$22.8K ﹤0.01% 2249
2025
Q2 		$62.5K Sell
455
-253
-36% -$37.2K ﹤0.01% 2895
2025
Q1 		$128K Sell
708
-692
-49% -$116K ﹤0.01% 1923
2024
Q4 		$219K Buy
+1,400
New +$248K ﹤0.01% 1904
2024
Q3 		– Sell
-238
Closed -$43.7K – 2630
2024
Q2 		$43.7K Sell
238
-14
-6% -$2.35K ﹤0.01% 3238
2024
Q1 		$44.8K Buy
+252
New +$35K ﹤0.01% 3211
2021
Q2 		– Sell
-602
Closed -$46K – 1486
2021
Q1 		$46K Sell
602
-6
-1% -$436 ﹤0.01% 1447
2020
Q4 		$36K Sell
608
-240
-28% -$12K ﹤0.01% 1444
2020
Q3 		$37K Buy
+848
New +$36.8K ﹤0.01% 1317

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pacer Advisors's KRYS Position: Q2 2026 in Review

Pacer Advisors reduced its Krystal Biotech (KRYS) stake by 48% in Q2 2026, selling an estimated $368K and leaving 1,315 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

Pacer Advisors first reported a position in KRYS in Q3 2020 and has held it in 12 quarters since. The position peaked at $658K in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Pacer Advisors held 1,315 shares of Krystal Biotech worth $489K as of Q2 2026.
  • Pacer Advisors sold 1,232 Krystal Biotech shares in Q2 2026, an estimated $368K.
  • Krystal Biotech made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1570 holding.
  • Pacer Advisors first reported a position in Krystal Biotech in Q3 2020 and has held it in 12 quarters since.
  • Pacer Advisors's Krystal Biotech position peaked at $658K in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.